Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CC Stock Summary
Top 10 Correlated ETFs
CC
In the News

Chemours (CC) Sets Up International F-gas Lifecycle Program
This program by Chemours (CC) will incorporate worldwide monitoring to stimulate further adoption, partnerships and reclamation.

Companies agree to pay $110M settlement for PFAS chemicals in Ohio
The Chemours Co. CC said Wednesday it reached a settlement with the State of Ohio along with DuPont de Nemours Inc. DD and Corteva Inc. CTVA for $110 million to resolve claims related to the manufacture and sale of per- and polyfluoroalkyl substances (PFAS). The agreement resolves Ohio's PFAS claims from the companies' facilities including the Washington Works plant along the Ohio-West Virginia border.

Chemours (CC) Boosts Low GWP HFC-152a Production by 20%
Chemours (CC) is increasing HFC-152a production by 20% at its Texas facility to meet the growing demand for eco-friendly propellants and foam-blowing agents.

These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

The Chemours Company (CC) Q3 2023 Earnings Call Transcript
The Chemours Company (NYSE:CC ) Q3 2023 Earnings Conference Call October 27, 2023 8:00 AM ET Company Participants Brandon Ontjes - Vice President of FP&A and Investor Relations Mark Newman - President and Chief Executive Officer Jonathan Lock - Senior Vice President and Chief Financial Officer Conference Call Participants Duffy Fischer - Goldman Sachs John McNulty - BMO Capital Markets Josh Spector - UBS Hassan Ahmed - Alembic Global Advisors Laurence Alexander - Jefferies Vincent Andrews - Morgan Stanley Operator Good morning. My name is Rob, and I will be your conference operator today.

Compared to Estimates, Chemours (CC) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

4 Chemical Stocks Set to Pull Off a Beat This Earnings Season
While softer demand in certain end markets is likely to be a drag, LyondellBasell (LYB), Chemours (CC), Axalta Coating Systems (AXTA) and Ashland (ASH) are likely to have benefited from cost and pricing actions.

Why Chemours (CC) Could Beat Earnings Estimates Again
Chemours (CC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

$7 Billion in Clean Hydrogen Grants: Winners and Losers
The US Department of Energy finally decided who would get a piece of the $7 billion Federal funding for green hydrogen, and the news may surprise you. The funding is intended to build green hydrogen infrastructure, but the terminology would be more suitable if it read “greener” hydrogen.

Chemours Announces Dates for Third Quarter 2023 Earnings Release and Webcast Conference Call
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Announces Dates for Third Quarter 2023 Earnings Release and Webcast Conference Call.
CC Financial details
CC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 33.53 | 30.17 | 38.47 | 43.73 | 0 | |
Net income per share | -0.32 | 1.33 | 3.69 | 3.72 | 0 | |
Operating cash flow per share | 3.94 | 4.9 | 4.97 | 4.85 | 0 | |
Free cash flow per share | 1.03 | 3.28 | 3.29 | 2.88 | 0 | |
Cash per share | 5.72 | 6.71 | 8.8 | 7.09 | 0 | |
Book value per share | 4.18 | 4.94 | 6.55 | 7.13 | 0 | |
Tangible book value per share | 3.16 | 3.93 | 5.91 | 6.39 | 0 | |
Share holders equity per share | 4.18 | 4.94 | 6.55 | 7.13 | 0 | |
Interest debt per share | 27.99 | 27.25 | 24.94 | 25.59 | 0 | |
Market cap | 2.98B | 4.08B | 5.54B | 4.76B | 0 | |
Enterprise value | 6.44B | 7.25B | 8.01B | 7.47B | 0 | |
P/E ratio | -57.34 | 18.64 | 9.1 | 8.23 | 0 | |
Price to sales ratio | 0.54 | 0.82 | 0.87 | 0.7 | 0 | |
POCF ratio | 4.59 | 5.06 | 6.75 | 6.31 | 0 | |
PFCF ratio | 17.64 | 7.56 | 10.19 | 10.64 | 0 | |
P/B Ratio | 4.33 | 5.02 | 5.12 | 4.3 | 0 | |
PTB ratio | 4.33 | 5.02 | 5.12 | 4.3 | 0 | |
EV to sales | 1.17 | 1.46 | 1.26 | 1.1 | 0 | |
Enterprise value over EBITDA | 13.37 | 8.75 | 6.65 | 6.2 | 0 | |
EV to operating cash flow | 9.91 | 8.99 | 9.77 | 9.9 | 0 | |
EV to free cash flow | 38.13 | 13.43 | 14.76 | 16.71 | 0 | |
Earnings yield | -0.02 | 0.05 | 0.11 | 0.12 | 0 | |
Free cash flow yield | 0.06 | 0.13 | 0.1 | 0.09 | 0 | |
Debt to equity | 6.39 | 5.26 | 3.63 | 3.44 | 0 | |
Debt to assets | 0.61 | 0.6 | 0.52 | 0.5 | 0 | |
Net debt to EBITDA | 7.18 | 3.83 | 2.06 | 2.25 | 0 | |
Current ratio | 1.8 | 1.83 | 1.8 | 1.7 | 0 | |
Interest coverage | 0.82 | 2.42 | 4.8 | 5.6 | 0 | |
Income quality | -12.5 | 3.68 | 1.35 | 1.3 | 0 | |
Dividend Yield | 0.06 | 0.04 | 0.03 | 0.03 | 0 | |
Payout ratio | -3.15 | 0.75 | 0.27 | 0.27 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0 | |
Intangibles to total assets | 0.02 | 0.02 | 0.01 | 0.02 | 0 | |
Capex to operating cash flow | -0.74 | -0.33 | -0.34 | -0.41 | 0 | |
Capex to revenue | -0.09 | -0.05 | -0.04 | -0.05 | 0 | |
Capex to depreciation | -1.55 | -0.83 | -0.87 | -1.05 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0.01 | 0 | 0 | |
Graham number | 5.45 | 12.15 | 23.31 | 24.42 | 0 | |
ROIC | 0.01 | 0.12 | 0.15 | 0.14 | 0 | |
Return on tangible assets | -0.01 | 0.03 | 0.08 | 0.08 | 0 | |
Graham Net | -27.76 | -26.17 | -23.81 | -27.42 | 0 | |
Working capital | 1.24B | 1.19B | 1.49B | 1.32B | 0 | |
Tangible asset value | 521M | 648M | 974M | 992M | 0 | |
Net current asset value | -3.79B | -3.63B | -3.12B | -3.32B | 0 | |
Invested capital | 6.39 | 5.26 | 3.63 | 3.44 | 0 | |
Average receivables | 767.5M | 592.5M | 615.5M | 673M | 0 | |
Average payables | 1.03B | 871.5M | 991M | 1.21B | 0 | |
Average inventory | 1.11B | 1.01B | 1.02B | 1.25B | 0 | |
Days sales outstanding | 44.52 | 37.54 | 41.42 | 33.63 | 0 | |
Days payables outstanding | 75.49 | 76.7 | 85.44 | 88.18 | 0 | |
Days of inventory on hand | 88.24 | 87.84 | 80.81 | 98.97 | 0 | |
Receivables turnover | 8.2 | 9.72 | 8.81 | 10.85 | 0 | |
Payables turnover | 4.84 | 4.76 | 4.27 | 4.14 | 0 | |
Inventory turnover | 4.14 | 4.16 | 4.52 | 3.69 | 0 | |
ROE | -0.08 | 0.27 | 0.56 | 0.52 | 0 | |
Capex per share | -2.92 | -1.62 | -1.68 | -1.98 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 11.44 | 8.12 | 10.31 | 11.02 | 10.01 | |
Net income per share | 1.54 | -0.59 | 0.97 | -2.52 | 0.13 | |
Operating cash flow per share | 1.94 | 0.97 | -0.8 | 0.41 | 0.87 | |
Free cash flow per share | 1.47 | 0.56 | -1.41 | 0.02 | 0.3 | |
Cash per share | 7.51 | 6.69 | 5.48 | 4.95 | 5.73 | |
Book value per share | 8.26 | 6.72 | 8.24 | 5.42 | 5.08 | |
Tangible book value per share | 7.52 | 6.02 | 7.49 | 4.69 | 4.37 | |
Share holders equity per share | 8.26 | 6.72 | 8.24 | 5.42 | 5.08 | |
Interest debt per share | 24.24 | 23.4 | 25.91 | 25.98 | 27.71 | |
Market cap | 3.83B | 5.04B | 4.46B | 5.5B | 4.17B | |
Enterprise value | 6.39B | 7.75B | 7.46B | 8.59B | 7.49B | |
P/E ratio | 3.99 | -13 | 7.69 | -3.66 | 52.11 | |
Price to sales ratio | 2.16 | 3.77 | 2.9 | 3.35 | 2.8 | |
POCF ratio | 12.72 | 31.52 | -37.49 | 90.17 | 32.07 | |
PFCF ratio | 16.73 | 54.22 | -21.24 | 1.83K | 94.75 | |
P/B Ratio | 2.98 | 4.56 | 3.64 | 6.81 | 5.52 | |
PTB ratio | 2.98 | 4.56 | 3.64 | 6.81 | 5.52 | |
EV to sales | 3.6 | 5.79 | 4.86 | 5.23 | 5.04 | |
Enterprise value over EBITDA | 15.85 | 86.15 | 24.08 | -27.88 | 85.12 | |
EV to operating cash flow | 21.23 | 48.46 | -62.72 | 140.77 | 57.62 | |
EV to free cash flow | 27.9 | 83.37 | -35.54 | 2.86K | 170.25 | |
Earnings yield | 0.06 | -0.02 | 0.03 | -0.07 | 0 | |
Free cash flow yield | 0.06 | 0.02 | -0.05 | 0 | 0.01 | |
Debt to equity | 2.9 | 3.44 | 3.11 | 4.73 | 5.53 | |
Debt to assets | 0.48 | 0.5 | 0.5 | 0.5 | 0.53 | |
Net debt to EBITDA | 6.35 | 30.12 | 9.69 | -10.02 | 37.75 | |
Current ratio | 1.82 | 1.7 | 1.83 | 1.54 | 1.68 | |
Interest coverage | 8.1 | 0.4 | 5.5 | -8.27 | -1.6 | |
Income quality | 1.25 | -1.65 | -0.82 | -0.16 | 6.84 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.16 | -0.38 | 0.26 | -0.1 | 1.85 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Intangibles to total assets | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | -0.24 | -0.42 | 0.76 | -0.95 | -0.66 | |
Capex to revenue | -0.04 | -0.05 | -0.06 | -0.04 | -0.06 | |
Capex to depreciation | -1.01 | -0.91 | -1.15 | -0.74 | -1.13 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 16.95 | 9.44 | 13.43 | 17.54 | 3.92 | |
ROIC | 0.05 | 0 | 0.04 | -0.07 | 0.01 | |
Return on tangible assets | 0.03 | -0.01 | 0.02 | -0.05 | 0 | |
Graham Net | -25.08 | -25.87 | -28.25 | -31.67 | -33.96 | |
Working capital | 1.59B | 1.32B | 1.46B | 1.18B | 1.49B | |
Tangible asset value | 1.17B | 992M | 1.12B | 700M | 650M | |
Net current asset value | -2.92B | -3.32B | -3.19B | -3.48B | -3.51B | |
Invested capital | 2.9 | 3.44 | 3.11 | 4.73 | 5.53 | |
Average receivables | 1.02B | 803M | 731.5M | 863.5M | 868M | |
Average payables | 1.26B | 1.26B | 1.21B | 1.09B | 955M | |
Average inventory | 1.27B | 1.36B | 1.45B | 1.47B | 1.38B | |
Days sales outstanding | 49.63 | 42.11 | 49.04 | 48.75 | 51.2 | |
Days payables outstanding | 84.98 | 99.11 | 89.85 | 73.65 | 67.24 | |
Days of inventory on hand | 88.39 | 111.23 | 114.5 | 105.55 | 98.06 | |
Receivables turnover | 1.81 | 2.14 | 1.84 | 1.85 | 1.76 | |
Payables turnover | 1.06 | 0.91 | 1 | 1.22 | 1.34 | |
Inventory turnover | 1.02 | 0.81 | 0.79 | 0.85 | 0.92 | |
ROE | 0.19 | -0.09 | 0.12 | -0.47 | 0.03 | |
Capex per share | -0.46 | -0.41 | -0.61 | -0.39 | -0.58 |
CC Frequently Asked Questions
What is The Chemours Company stock symbol ?
The Chemours Company is a US stock , located in Wilmington of De and trading under the symbol CC
Is The Chemours Company buy or a sell ?
7 stock analysts have 7 predictions with a medium analyst target price of $38.71. The lowest prediction is $33 and the highest is $48
What is CC stock prediction ?
With a median analyst target price of $36.5, 2 stock analysts have made 2 forecasts in last 90 days. $33 is the lowest and $40 is the greatest projection.
What is The Chemours Company stock quote today ?
The Chemours Company stock price is $28.9 today.
Is The Chemours Company stock public?
Yes, The Chemours Company is a publicly traded company.